Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
SpringWorks Therapeutics
Biotech
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Ex-CRISPR Tx CMO lands at Takeda. Lexeo adds Pfizer rare disease leader as development chief. Merck & Co. leader to join Cartography.
Max Bayer
,
Gabrielle Masson
Feb 9, 2024 9:30am
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Feb 6, 2024 9:50am
SpringWorks eyes AstraZeneca's Koselugo market with phase 2 data
Nov 16, 2023 10:59am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
SpringWorks enjoys double payday from GSK deal, $225M funding
Sep 7, 2022 10:49am
SpringWorks' stock jumps as phase 3 tumor trial hits goal
May 24, 2022 8:24am
